Document is current
Any future updates will be listed below
-
Authors
Morse, Michael A.
Crosby, Erika J. https://orcid.org/0000-0002-4872-6711
Force, Jeremy
Osada, Takuya
Hobeika, Amy C.
Hartman, Zachary C. https://orcid.org/0000-0001-6549-8207
Berglund, Peter
Smith, Jonathan
Lyerly, H. Kim https://orcid.org/0000-0002-0063-4770
-
Funding
Funding for this research was provided by:
Merck
Merck
Merck
Merck
Merck
Merck
Merck
- License Information
-
More Information
Article History
Received: 19 December 2021
Revised: 15 December 2022
Accepted: 5 January 2023
First Online: 10 February 2023
Competing interests
: ZCH and HKL have equity in Replicate and serve on the Scientific Advisory Board. HKL has equity in Alphavax. JS has equity in AlphaVax and VLP Therapeutics, and is employed by VLP Therapeutics. PB has equity in AlphaVax and HDT Bio, and is employed by HDT Bio.
: The Duke University Institutional Review Board approved the clinical trial of pembrolizumab plus VRP-HER2 and all patients provided written informed consent prior to any study related activities.
